Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019-December 2020

被引:10
作者
Cremer, Laura J. [1 ]
Board, Amy [1 ,2 ]
Guy, Gery P., Jr. [1 ]
Schieber, Lyna [1 ]
Asher, Alice [3 ]
Parker, Erin M. [1 ]
机构
[1] Natl Ctr Injury Prevent & Control, Div Overdose Prevent, Atlanta, GA USA
[2] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA
[3] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA USA
关键词
Medication for opioid use disorder; COVID-19; Naloxone; Buprenorphine; Extended-release naltrexone; SUBSTANCE USE; IMPACT;
D O I
10.1016/j.drugalcdep.2021.109192
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: COVID-19 stay-at-home orders may reduce access to substance use treatment and naloxone, an opioid overdose reversal drug. The objective of this analysis was to compare monthly trends in pharmacy-based dispensing rates of medications for opioid use disorder (MOUD) (buprenorphine and extended-release [ER] naltrexone) and naloxone in the United States during March 2019-December 2020 by age and sex. Methods: We calculated monthly prescription dispensing rates per 100,000 persons using IQVIA New to Brand. We used Joinpoint regression to calculate monthly percent change in dispensing rates and Wilcoxon Rank Sum tests to examine differences in median monthly rates overall, and by age and sex between March 2019-December 2019 and March 2020-December 2020. Results: Buprenorphine dispensing increased among those aged 40-64 years and >= 65 years from March 2019 to December 2020. Median rates of total ER naltrexone dispensing were lower in March 2020-December 2020 compared to March 2019-December 2019 for the total population, and for females and males. From March 2019 to December 2020, ER naltrexone dispensing decreased and naloxone dispensing increased for those aged 20-39 years. Conclusions: Dispensing ER naltrexone declined during the study period. Given the increase in substance use during the COVID-19 pandemic, maintaining equivalent access to MOUD may not be adequate to accommodate rising numbers of new patients with opioid use disorder. Access to all MOUD and naloxone could be further expanded to meet potential needs during and after the public health emergency, given their importance in preventing opioid overdose-related harms.
引用
收藏
页数:10
相关论文
共 56 条
  • [1] [Anonymous], 2022, PROVISIONAL DRUG OVE
  • [2] Alderks C.E., 2017, CBHSQ REPORT, P2013
  • [3] A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in US office-based practices
    Andraka-Christou, Barbara
    Capone, Matthew J.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 54 : 9 - 17
  • [4] Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality An Audit Study
    Beetham, Tamara
    Saloner, Brendan
    Wakeman, Sarah E.
    Gaye, Marema
    Barnett, Michael L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2019, 171 (01) : 1 - +
  • [5] Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic
    Cance, Jessica Duncan
    Doyle, Erin
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (23): : 2442 - 2444
  • [6] Adherence to Extended Release Naltrexone: Patient and Treatment Characteristics
    Chang, Grace
    Crawford, Mitchell
    Pitts, Michelle
    Schein, Abigail Z.
    Goodwin, Katherine
    Enggasser, Justin L.
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2018, 27 (06) : 524 - 530
  • [7] Addressing co-occurring public health emergencies: The importance of naloxone distribution in the era of COVID-19
    Collins, Alexandra B.
    Ndoye, Colleen Daley
    Arene-Morley, Diego
    Marshall, Brandon D. L.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 83
  • [8] With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic
    Courser, Matthew W.
    Raffle, Holly
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 122
  • [9] Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
    Currie, Janet M.
    Schnell, Molly K.
    Schwandt, Hannes
    Zhang, Jonathan
    [J]. JAMA NETWORK OPEN, 2021, 4 (04)
  • [10] Czeisler MÉ, 2020, MMWR-MORBID MORTAL W, V69, P1049, DOI [10.1101/2020.04.22.20076141v1, 10.15585/mmwr.mm6932a1]